Cerrar

Bioinicia introduces its GMP manufacture of electrospun drug delivery products

Bioinicia was present at UK-China Mini-Symposium on Electrospinning for Drug Delivery introducing a case study

Bioinicia S.L.

Bioinicia S.L.

Publicado el jueves, 26 de abril de 2018 a las 15:48

The UK-China Mini-Symposium on Electrospinning for Drug Delivery took place last April 18th at University College London’s School of Pharmacy. This event welcomed many experts in the electrospinning field, as well as professors and students from pharmaceutical and biomedical sectors.

Dr. Tom Hayes, Product & Technology Specialist of Bioinicia, was there presenting "GMP manufacture of electrospun drug delivery products: A first case study". His introduction was warmly received and he had the opportunity to present Bioinicia´s state-of-the art project with Dermtreat ApS, a Danish-based biopharmaceutical company focused on innovative approaches to the treatment of mucosal diseases.

Bionicia is currently manufacturing, in behalf of Dermtreat ApS, the novel Rivelin® patch which provides uni-directional mucosal drug delivery for the treatment of Oral Lichen Planus, a chronic condition that affects 1-2% of the population.

Recently, Eureka by PatSnap, the newsletter for R&D, IP and innovation experts, has published a post on electrospinning technology in regards to this event. In this publication they show the electrospinning process concisely and how Bioinicia produce clinical grade electrospun biomaterials. The newsletter states that our client DermtreatApS is the most patent-intensive new electrospinning for medical purposes company.

About Bioinicia

Bioinicia S.L. is a privately held materials science and engineering company dedicated to the development, industrial scale-up and manufacturing of nano- and microstructured materials by electro-hydro dynamic processes (i.e. electrospinning and electrospraying) for their clients and providing premium quality equipment for laboratory to industrial-scale processing.

Bioinicia acts as a partner for product development, electrospinning-electrospraying technology and industrial manufacturing.

For additional information, please visit www.bioinicia.com.

About Dermtreat

Dermtreat ApS is a Danish-based, private, biopharmaceutical company focused on innovative approaches to the treatment of mucosal diseases. Dermtreat’s lead product candidate is using its novel Rivelin® patch for the treatment of Oral Lichen Planus, a chronic condition that affect 1-2% of the population. The Rivelin® patch incorporates clobetasol propionate to treat OLP and is planned to commence a clinical Phase 2b study in April 2018.

Shareholders include Sofinova Ventures, Lundbeckfonden Emerge, Novo Seeds and Welfare Tech Invest.

For additional information, please visit www.rivelin.eu.

7.161 visitas

Utilizamos cookies propias y de terceros para ofrecerte toda la funcionalidad y una mejor experiencia, obtener estadísticas de tráfico, analizar el uso de la web y mejorar nuestros servicios.
Tienes disponible aquí nuestra política de cookies.
Puedes aceptar todas nuestras cookies pulsando el botón 'ACEPTAR' o configurar aquí tus preferencias.

Estrictamente necesarias +

Estas cookies son necesarias ya que permiten que el sitio web funcione correctamente, no se pueden desactivar.

Estadísticas +

Son las cookies que utilizamos exclusivamente con fines estadísticos para poder analizar cómo los usuasrios hacen uso de la web. Recopila información anónima tal como el número de visitantes del sitio, o las páginas más populares. Activar estas cookies nos permite seguir mejorando.

Funcionales +

Estas cookies son necesarias para el intercambio y presentación de contenidos de plataformas externas como youtube o de redes sociales como facebook, twitter o linkedin.

Marketing y publicidad +

Estas se utilizan para crear perfiles de usuario y analizar la efectividad de campañas publicitarias o para rastrear al usuario en un sitio web o en varios sitios web con fines de marketing similares..

GUARDAR AJUSTESACEPTO